Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

NCT01375777 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

411

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipidemia

Interventions

BIOLOGICAL: Evolocumab
DRUG: Ezetimibe
OTHER: Placebo to Evolocumab

Sponsor

Amgen